Moreover, a retrospective analysis of 809 patients with R/R diffuse large B cell lymphoma (DLBCL) treated with axicabtagen–ciloleucel (using a CD28 costimulatory endodomain in a gammaretroviral vector) demonstrated higher efficacy but also higher toxicity compared to tisagenlecleucel (that uses a 4-1BB costimulatory endodomain in a lentiviral vector) [39]. Here, CD28 is linked to diffuse large B-cell lymphoma.